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Bulfone has dual qualiﬁcations in pharmacy and health econom-
ics and is currently a Senior Research Fellow (Health Economics)
at Deakin University, Melbourne, Australia. She was the Project
Manager, for over 5 years (ending July 2007), at the Monash
Evaluation Group (MEG), Melbourne, Australia, located within
the Centre for Health Economics at Monash University. The
MEG was contracted by the Australian Government’s Depart-
ment of Health and Aging to provide timely advice, in the form
of written commentaries, on submissions to the Australian Phar-
maceutical Beneﬁts Advisory Committee (PBAC) requesting gov-
ernment subsidy of pharmaceutical preparations. As Project
Manager, Ms. Bulfone was responsible for reviewing the content,
internal consistency, and clarity of all commentaries produced at
MEG, and ensuring that each commentary clearly and concisely
identiﬁed the main facts and issues arising from the major sub-
mission for the PBAC. Ms. Bulfone has an extensive understand-
ing of technology assessment in Australia, particularly in relation
to pharmaceuticals and medical services, where she has contrib-
uted to the drafting and improvement of the economic guidelines
for both Australia’s PBAC and Medical Services Advisory Com-
mittee (MSAC). She has a thorough and in-depth knowledge of
the Australian Pharmaceutical Beneﬁts Scheme (PBS) and the
system through which submissions for listing pharmaceutical
preparations on the PBS are processed.
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is now Senior Vice President for Health Economics at United
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ogy led to applied research for the Health Technology Assessment
Council of Quebec, a pioneer in the then nascent ﬁeld. This early
interest in the proper approach to evaluating health-care interven-
tions has resulted in efforts to help government organizations
in countries as diverse as Germany and Colombia develop and
implement their methodologies; and to appointments on the
steering committees of various global initiatives to address speciﬁc
diseases. In addition to Dr. Caro’s work and publications on more
than 100 disease models, he has continued active research
on methods for modeling diseases and the application of epide-
miologic concepts to economic studies. This has included the
development of approaches for dealing with complex time
dependencies and the transfer of modeling techniques from other
ﬁelds to medicine—modifying discrete event simulation for use in
economic and risk-beneﬁt analyses and the modeling of adaptive
clinical trials.More recently, he has focused on the development of
a suitable metric to guide health-care decisions.
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trative Studies from the AustralianNational University, Canberra,
Australia, and a PhD from Monash University, Melbourne, Aus-
tralia. Dr. Carter is Foundation Chair in Health Economics at
Deakin University, after 6 years as Head of the University of
Melbourne Health Economics Group. Previously, Dr. Carter was
DeputyDirector of theMonashUniversityHealth EconomicsUnit
(1993–1999) and Head of the Economics and Evaluation Unit at
the Australian Institute of Health and Welfare (1990–1993). He is
widely recognized for his expertise in economic appraisal, both
nationally and internationally. In Australia, for example, he was
appointed by the Commonwealth Health Minister to serve on a
range of key government committees, such as the Pharmaceuticals
Beneﬁts Advisory Committee (2000–2004) and the Australian
Screening Advisory Committee (2004–2006); and by the Victo-
rian Health Minister to serve on the Victorian Policy Advisory
Committee on Clinical Practice and Technology. At the interna-
tional level, Dr. Carter’s recognition is evidenced by invitations to
speak at international forums, as well as the invitation from the
Commonwealth Secretariat in London to provide expert advice on
priority setting to Commonwealth Health Ministers.
Hans-Peter Dauben, MD. Hans-Peter Dauben received his edu-
cation from Heinrich-Heine-Universität, Düsseldorf, Germany.
After ﬁnalizing his training as a cardiac surgeon at the University
of Düsseldorf, Düsseldorf, Germany, he moved to the German
Institution for Medical Documentation and Information
(DIMDI), an institution within the scope of the federal ministry
of health, to establish the German Agency for health technology
assessment (HTA) at DIMDI on behalf of the federal ministry in
2000 and to develop structural access to HTA information, pri-
ority setting in HTA, and other developments to establish a broad
consensus on HTA in Germany. Since 2006, Dr. Dauben is also
working as a consultant for the public health institution Lande-
sinstitut für Gesundheist und Argeit (LIGA.NRW) of
Northrhine-Westfalia in Bielefeld/Germany, a public institution
within the scope of the state ministry of health. At the University
of Cologne, he lectures on HTA and evidence-based medicine. He
is mainly involved in courses on HTA with dedicated user groups
in the ﬁeld of health quality assurance, as well as pharmacists and
physicians in cooperation with professional organizations. His
research interests are mainly focused on informed decision-
making processes, including the methodological development
of HTA, systematic evaluation of health needs in health-care
systems, support systems for innovations in health-care manage-
ment, and improving knowledge management in evidence-based
health-care systems internationally.
Michael Drummond, BSc, MCom, DPhil. Michael Drummond
received a DPhil in Economics from University of York, York,
UK, a Masters of Commerce in Business Administration from the
University of Birmingham, Birmingham, United Kingdom, and a
BSc Honours (Class 1) Industrial Metallurgy from University of
Birmingham. He is currently a Professor of Health Economics at
the Centre for Health Economics, University of York and former
Director of the Centre for Health Economics at the University of
York. Dr. Drummond’s particular ﬁeld of interest is in the eco-
nomic evaluation of health-care treatments and programs. He
has undertaken evaluations in a wide range of medical ﬁelds
including care of the elderly, neonatal intensive care, immuniza-
tion programs, services for people with AIDS, eye health care,
and pharmaceuticals. He is the author of two major textbooks
and more than 500 scientiﬁc papers, has acted as a consultant to
the World Health Organization, and was Project Leader of a
European Union Project on the Methodology of Economic
Appraisal of Health Technology. He has been President of the
International Society of Technology Assessment in Health Care,
and the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). He is currently a member of the10.1111/j.1524-4733.2009.00560.x
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and Clinical Excellence in the United Kingdom, and is a Principal
Consultant for i3 Innovus.
David M. Eddy, MD, PhD. David Eddy received a BA and PhD
in Engineering–Economic Systems (Applied Mathematics) from
Stanford University, Palo Alto, California, USA, and an MD from
the University of Virginia, Charlottesville, Virginia, USA in 1968.
He was Professor of Engineering and Medicine at Stanford, and
then the J. Alexander McMahon Professor of Health Policy and
Management at Duke University, Durham, North Carolina, USA.
He is the founder and coinventor of the Archimedes model, and
is currently the Medical Director of Archimedes, Inc. in San
Francisco, California, USA. Dr. Eddy is the author of ﬁve books
and more than 100 ﬁrst-authored papers, including a series of 30
essays for the Journal of the American Medical Association. His
writings span from technical mathematical theories to broad
health policy topics. He has received eight national and interna-
tional awards in several different ﬁelds, including applied math-
ematics, HTA, health-care quality, and outcomes research. He
has been elected or appointed to more than 40 national and
international boards and commissions—including Consumers
Union, the National Board of Mathematics, the World Health
Organization Panel of Experts, the Blue Cross Blue Shield
Medical Advisory Panel, and the National Committee for
Quality Assurance—and has been a member of the Institute of
Medicine/National Academy of Sciences since 1984.
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ter’s degree in business administration from the Christian-
Albrechts-University, Kiel, Germany and a PhD in Economics
from the Bayreuth University, Bayreuth, Germany. He is Principal
of Health Economics and Outcomes Research at IMS Health in
Germany, with a particular focus on health economic evaluations
(cost analysis, economic modeling, cost-effectiveness analysis),
market access strategies, and health policy. Formerly cofounder
and managing director of Fricke & Pirk, Dr. Fricke previously
worked for several years in the pharmaceutical industry in health
economics, pricing, and health policy, latterly as head of health
economics at Novartis Pharma in Nuremberg, Germany. Dr.
Fricke’s professional experience encompasses health economic
evaluations across a range of markets and numerous therapeutic
areas. His focus is on health economic evaluations (cost analysis,
economic modeling, cost-effectiveness analysis), market access
strategies, and health policy. He is a member of ISPOR. He has
served as a lecturer for the Friedrich-Schiller-Universität Jena, the
Hannover Medical School, the University of Applied Sciences in
Deggendorf, and various other educational institutions in
Germany.
Devidas Menon, MHSA, PhD, BSc. Devidas Menon received an
MHSA from the University of Alberta, Edmonton, Canada, a
PhD in Physics from the University of Alberta, Edmonton, and a
BSc (Hons) in Physics from the University of Singapore, Sin-
gapore. He is Professor at the Department of Public Health
Sciences, School of Public Health, University of Alberta, Edmon-
ton. Previously, he has held the positions of Executive Director
and CEO, Institute of Health Economics in Edmonton, and
Executive Director, Canadian Coordinating Ofﬁce for Health
Technology Assessment (now the Canadian Agency for Drugs
and Technologies in Health) in Ottawa, Ontario, Canada. Dr.
Menon has written many papers, conference abstracts, and book
chapters. He has been a reviewer for numerous journals, includ-
ing the Canadian Journal of Cardiology, International Journal of
Technology Assessment in Health Care, Canadian Medical Asso-
ciation Journal, Pharmacoeconomics, Health Policy and The
Milbank Quarterly. He is currently a member of the Canadian
Institutes of Health Research’s Health Policy and Systems Man-
agement Research Peer Review Committee. Dr. Menon and Ms.
Staﬁnski have been engaged in HTA for many years. They have
published in the area of priority-setting for HTA, conducted
speciﬁc HTAs, worked with governments on HTA, and have been
involved actively with Health Technology Assessment Interna-
tional. They also teach a course on HTA in the School of Public
Health at the University of Alberta.
David W. Miller, PhD. David Miller received a PhD from the
University of Maryland at Baltimore, Maryland, USA and a BS
from the University of Iowa, Iowa City, Iowa, USA. He is Owner
and Principal of Miller Pharma Consulting. His previous roles
include Vice President of Pharmacoeconomics and Site Head at
Elan Pharmaceuticals, and Vice President of Global Health Out-
comes at GlaxoSmithKline. He holds appointments at the Uni-
versity of North Carolina and the University of California, San
Francisco, California, USA. Dr. Miller has lived and worked
internationally for over half of his career and is the author or
coauthor of more than 70 scientiﬁc publications. He served as a
Director on the Board of Directors of Elan Pharma Ltd., was
vice-chair of PhRMA’s Health Outcomes Committee, and is a
member of ISPOR and the ISPOR Institutional Council. Dr.
Miller was past-Chairman of the Board of Grants for the Ameri-
can Foundation for Pharmaceutical Education, is a member of
the Dean’s Advisory Board at the University of California, San
Francisco, and is an adjunct professor in pharmaceutical policy
at the University of North Carolina, Durham, North Carolina,
USA.
Peter J. Neumann, ScD. Peter J. Neumann received his doctorate
in health policy and management from Harvard University,
Boston, Massachusetts, USA, and a BA and MA in Economics
from University of Pennsylvania, Philadelphia, Pennsylvania,
USA. He is the Director of the Center for the Evaluation of Value
and Risk in Health at the Institute for Clinical Research and
Health Policy Studies at Tufts Medical Center, and Professor of
Medicine at Tufts University School of Medicine. Prior to joining
Tufts, he was on the faculty of the Harvard School of Public
Health for 10 years, most recently as Associate Professor of
Policy and Decision Sciences. His research focuses on the role of
cost-effectiveness analysis and risk–beneﬁt trade-offs in health-
care decision-making. He is the author or co-author of over 100
papers in the medical literature, and the author of Using Cost-
Effectiveness Analysis to Improve Health Care (Oxford Univer-
sity Press, 2005). He is a contributing editor of Health Affairs
and member of the editorial board of Value in Health. Dr.
Neumann has served as President of ISPOR and as a trustee of
the Society for Medical Decision Making.
John C. O’Donnell, PhD. John C. O’Donnell received his PhD in
Health Policy and Administration from the University of North
Carolina at Chapel Hill, School of Public Health, Department of
Health Policy and Administration, Chapel Hill, North Carolina,
USA. Dr. O’Donnell received a Master of Arts degree from the
Nelson A. Rockefeller College of Public Affairs and Policy, State
University of New York at Albany, New York, USA and a Bach-
elor of Arts in Pre-Law/Social Sciences from Saint Bonaventure
University, St. Bonaventure, NY. He is currently the Vice Presi-
dent of Global Health Outcomes at Bristol-Myers Squibb Co.,
located in Princeton, NJ. Previously, he was Executive Director,
Health Care Relations, External Medical Relations, Astra-
Zeneca, in Wilmington, Delaware and also was the Global
Lead, Global Health Economics and Outcomes Research with
AstraZeneca. Dr. O’Donnell has professional experience and
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doctoral-level training in econometrics, policy analysis, and
health services research. Professional societies include Academy
Health, American Public Health Association, and ISPOR. He has
over 55 publications and proceedings to his credit, mainly in the
areas of outcomes research and policy.
Chris L. Pashos, PhD. Chris L. Pashos holds a PhD and MPP in
Public Policy from Harvard University, Boston, Massachusetts,
USA and a BS with distinction from the United States Naval
Academy, Annapolis, Maryland, USA. In a career spanning 30
years, Dr. Pashos has served in leadership positions in academia,
business, and government. Currently Vice President at Abt Bio-
Pharma Solutions Inc., he created and leads its Health Economic
Research & Quality of Life Evaluation Services (HERQuLES)
team. HERQuLES collaborates internationally with clinicians,
researchers, and policymakers to assess the use, outcomes, and
value of medicines, medical devices, biotechnology processes, and
other health-care products and services. Previously, Dr. Pashos
was on the faculty of Harvard Medical School. Having lived in
North America and Europe and worked around the world, Dr.
Pashos has designed and implemented prospective observational
studies involving hundreds of thousands of patients. His “real-
world” research expertise extends also to retrospective database
analyses in numerous therapeutic areas, notably cardiometabolic
diseases, cancer and women’s health. This work has resulted in
more than 70 indexed, peer-reviewed articles; more than 140
presentations, book chapters, and reports; and input to UNICEF,
NIH, the US Surgeon General, the US Congress, and others. Dr.
Pashos is a recipient of the Distinguished Service Award bestowed
by ISPOR. He was chair of the ISPOR Institutional Council in
2007, and ISPOR President for 2008–2009.
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University of Arizona, Tucson, Arizona. She has 16 years of
experience in the pharmaceutical industry before establishing her
outcomes research consulting company, Sissi Pham Consulting,
Inc., which is located in Chapel Hill, North Carolina, USA. Ms.
Pham was the Regional Head of Global Health Outcomes at
GlaxoSmithKline. Ms. Pham has an academic appointment with
the University of Arizona, where she serves as Associate Clinical
Professor at the College of Pharmacy. She served as the ISPOR
Institutional Council Chair, 2004–2006. She continues to be
active with PhRMA and ISPOR initiatives related to beneﬁt–risk,
HTAs, and evidence-based medicine.
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College of Medicine, Iowa City, Iowa and a BS in Economics and
General Science from the University of Iowa. He is a general
internist and health economist. He is a Full Member in the
Cancer Prevention Program, Division of Public Health Science at
the Fred Hutchinson Cancer Research Center. Dr. Ramsey is a
Professor in the School of Medicine, School of Pharmacy, and
the Institute for Public Health Genetics at the University of
Washington, Seattle, Washington, USA. He also directs the
Cancer Prevention and Survivorship Program at the Seattle
Cancer Care Alliance. His current studies—funded by the
National Cancer Institute, National Human Genome Research
Institute, Centers for Disease Control and Prevention, and
several pharmaceutical manufacturers—include projects to
develop a genetic screening policy model for colorectal cancer, a
multicenter study of decision-making for men with newly diag-
nosed prostate cancer, and studies of cancer screening, incidence,
treatment, and outcomes for Native Americans diagnosed with
cancer. Along with investigators at the University of Washington,
Dr. Ramsey codirects an NCI-funded training program in Bio-
behavioral and Cancer Outcomes Research. He is a member of
the Institute of Medicine’s National Cancer Policy Forum.
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mittee of Revision, United States Pharmacopoeia. She also was a
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entists, a nonproﬁt scientiﬁc organization, and is a member of the
American Society of Association Executives as well as many
pharmacy organizations.
Corinna Sorenson, MPH, MA. Corinna Sorenson holds a Master
of Public Health and Master of Health Services Administration,
with emphasis in health policy and health economics from the
University of Michigan, Ann Arbor, Michigan, USA and is a PhD
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pricing and reimbursement, economic evaluation, patient safety,
medical product innovation, and risk communication. In addi-
tion, she has held other health policy research positions at Stan-
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taken research on HTA systems, the ﬁnancing of medical devices,
and public health policies in Europe. Ms. Sorenson has authored
over 20 publications.
Tania D. Staﬁnski, MS. Tania Staﬁnski is completing a Doctor of
Philosophy in Public Health from the University of Alberta,
Edmonton, Alberta, Canada. She received an MS in Medical
Sciences in Epidemiology and a BS in Microbiology, University of
Alberta, Edmonton, Alberta. Ms. Staﬁnski is presently Research
Program Coordinator at the School of Public Health, University
of Alberta, where she also directs its Health Technology and
Policy Unit. Previously, she held research positions at the Institute
of Health Economics, Edmonton, Alberta, and within the
Department of Public Health Sciences at the University of
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